The University of Texas MD Anderson Cancer Center
1515 Holcombe Boulevard
Houston
Texas
77030
United States
Tel: 1-877-731-7527
Website: http://www.mdanderson.org/
318 articles about The University of Texas MD Anderson Cancer Center
-
Clinical Catch-Up: September 21-25
9/28/2020
The European Society of Medical Oncology (ESMO) Virtual Congress 2020 was last weekend and the beginning of the week, which resulted in numerous clinical trial announcements. Here’s a look. -
The European Society for Medical Oncology (ESMO) Virtual Congress 2020 was this weekend, with numerous companies presenting clinical trial data and updates.
-
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
-
Astex Pharmaceuticals and MD Anderson Announce Strategic Collaboration to Accelerate Clinical Evaluation of Therapies for Patients with Leukemia
9/8/2020
Astex Pharmaceuticals, Inc., and The University of Texas MD Anderson Cancer Center announces a strategic collaboration agreement aimed at accelerating the clinical evaluation of Astex’s pipeline of products for patients with certain types of leukemia, including myelodysplastic syndromes, chronic myelomonocytic leukemia and acute myeloid leukemia.
-
Xencor and MD Anderson Enter Strategic Collaboration to Advance Investigational XmAb® Drug Candidates
9/3/2020
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to study investigational treatments for pa
-
WAT Medical Enterprise Contributes to M.D. Anderson Cancer Center
8/31/2020
WAT Medical Enterprise has been supporting the world's cancer research. They donated part of the profits from selling EmeTerm on Amazon to the M.D. Anderson Cancer Center to support the development of global cancer. After making the donation in August 2019 , WAT Medical Enterprise will continue to support the cause of M.D. Anderso
-
Perimeter Medical Imaging Announces Expansion of ATLAS AI Project with Installation of OTISTM for AI development at Leading Cancer Care Center, MD Anderson
7/27/2020
400 Patients Expected to be Enrolled in CPRIT-Backed Artificial Intelligence Development Study in Breast Cancer
-
Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development
7/14/2020
New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
-
Paris-based Sanofi and Houston-based The University of Texas MD Anderson Cancer Center entered a five-year strategic partnership to develop immune therapies and targeted cancer treatments.
-
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies
5/5/2020
Licensed technologies include use of Genprex’s TUSC2 gene therapy combined with immunotherapy drugs
-
Clinical Catch-Up: April 27-May 1
5/4/2020
There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look. -
MD Anderson Cancer Center Now Enrolling Patients in Rafael Pharmaceuticals’ Phase 2 Clinical Trial of CPI-613® (devimistat) for Relapsed or Refractory Burkitt’s Lymphoma/Leukemia
4/28/2020
Patients will be assessed in advance of enrollment to ensure safety, due to COVID-19 pandemic
-
NuProbe Announced New Clinical Advisory Board Members from Yale and MD Anderson, Launched NGS Multi-gene Panels
4/22/2020
NuProbe, a molecular diagnostic startup, announced the addition of two world-renowned oncologists to their clinical advisory board: Amir A. Jazaeri, M.D., from the University of Texas MD Anderson Cancer Center and Abhijit Patel, M.D., Ph.D., from Yale University School of Medicine.
-
Bellicum Completes Sale of Houston Facility
4/15/2020
Purchase price of $15 million from sale of manufacturing, office and laboratory facility
-
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018 as Monotherapy and Combination Therapy in Patients with Uveal Melanoma and NRAS mutant Metastatic Melanoma in the United States
3/17/2020
InxMed Co., Ltd. announced that the company has dosed first patient in its Phase Ib clinical trial of IN10018 as monotherapy and in combination with MEKi in the patients either with metastatic uveal melanoma or NRAS mutant metastatic melanoma at The University of Texas M. D. Anderson Cancer Center, United States.
-
Soliton signs Agreement with Global Manufacturer Sanmina
3/9/2020
Expects Delivery and Sales of Initial RAP Devices for Tattoo Removal in Mid-2020
-
Osteosarcoma profiling reveals why immunotherapy remains ineffective
2/24/2020
Study points to strategies for improving outcomes with immunotherapy in rare cancer type
-
Intratumoral heterogeneity may be responsible for chemotherapy resistance in patients with small cell lung cancer
2/17/2020
Small cell lung cancer accounts for 14% of all lung cancers and is often rapidly resistant to chemotherapy, resulting in poor clinical outcomes.
-
Clinical Catch-Up: February 10-14
2/17/2020
It was a very busy week for clinical trial news. Here’s a look.